US Healthcare & Drug Pricing Debate
Harvard Biotech Club x Roivant Sciences
Trump and Bernie can agree on one thing: they’re both worked up about the cost of prescription drugs, and they’re not alone. 80% of Americans believe that drug prices are unreasonable. Are they right? Why do medicines cost so much in the US? Why can’t the government negotiate drug prices? What can be done about it??
Come hear the thoughts of health care experts. Ask questions on current policies.
Hosted and Moderated by:
Vivek Ramaswamy ‘07
Founder & CEO, Roivant Sciences
Vivek Ramaswamy (College ’07) is an American entrepreneur in the biotechnology sector. He is the founder and CEO of the pharmaceutical company Roivant Sciences, founded in 2014 and now valued at $7 billion. Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients.
Opening 2 minute flash talks by:
Aseda Tena - GSAS Biomedical PhD Student
Mark Zaki - HMS MD student
Kristina Wang - HBS MBA student
Nima Shamtoub - HLS JD student
Joining us for this special event:
Peter Kolchinsky, Ph.D. ‘01
Co-founder, Portfolio Manager, & Managing Director, RA Capital Management
Peter Kolchinsky (Ph.D ’01) is co-founder, Managing Director, and Portfolio Manager of RA Capital Management, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves as a member of the Board of Directors for a number of private companies. He is the author of “The Entrepreneur’s Guide to a Biotech Start-up” and the Biotech Social Contract series.
John Maraganore, Ph.D.
CEO and Director, Alnylam Pharmaceuticals
John Maraganore is the CEO and Director of Alnylam Pharmaceuticals, a biopharmaceutical company focused on translating RNA interference (RNAi) into a whole new class of innovative medicines. He has been responsible for company franchises across oncology, and cardiovascular, inflammatory, and metabolic diseases and led the discovery and development of Angiomax™. He currently serves as the chair of the Biotechnology Industry Organization (BIO) and on the board of Agios Pharmaceuticals.
Vice President, Controlling Health Care Costs and Advancing Medicare, The Commonwealth Fund
Shawn Bishop is the Vice President for the Controlling Health Care Costs program at the Commonwealth Fund, which aims to promote a high-performing health care system that achieves better access, improved quality, and greater efficiency, particularly for society’s most vulnerable, including low-income people, the uninsured, and people of color. Previously, she provided strategic consulting related to Medicare and the Affordable Care Act, including policy development and outreach to Congress and the administration. Bishop earlier served as senior vice president of research for the Marwood Group, offering financial services firms and others analysis of political, legislative, and regulatory environments, and as professional staff with the U.S. Senate Finance Committee.